Cantor Fitzgerald Reiterates Bullish View on Corbus Pharmaceuticals (CRBP) on Resunab Success
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Aegis Capital Affirms Corbus Pharma (CRBP) at 'Buy' Following Strong Resunab Phase 2 Data
November 14, 2016 2:49 PM ESTAegis Capital affirms Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) at Buy with a price target of $12 after the company announced positive topline results from its Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis.
The firm commented today, We... More
Corbus Pharma (CRBP) Announces Topline Data from Resunab Phase 2 in SS Diffusion; Meaningful CRISS Score Noted
November 14, 2016 6:33 AM ESTCorbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) announced positive topline results from its Phase 2 study evaluating Resunab ("JBT-101") for the treatment of diffuse cutaneous systemic sclerosis ("systemic sclerosis"). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. The higher the CRISS score the greater the improvement; a CRISS... More
